Former pear therapeutics executives start new vc firm, with biotech veteran bob langer as adviser

Executives from the shuttered digital health company Pear Therapeutics are launching a new VC firm, offering early access to new startups formed by serial biotech entrepreneur Bob Langer.

Former Pear CEO Corey McCann and former licensing head Michael Langer formed the new firm, T.rx Capital, earlier this year, according to three people with knowledge of the firm and documents

reviewed by STAT. Michael Langer, the son of Bob Langer, confirmed the news and that they had set a $175 million cap for its first fund. The firm will invest in therapeutics and digital

health products by both forming new companies and taking pitches from early-stage startups. T.rx has brought in Everly Health executive Liz Kwo and Caris Life Sciences vice president Debbie

Lin as venture partners, while current Eli Lilly business development team member Kwesi Frimpong-Boateng will be joining T.rx’s founding team. Bob Langer is a scientific adviser. STAT+

Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS DAILY COVERAGE AND ANALYSIS OF THE BIOTECH SECTOR — BY SUBSCRIBING

TO STAT+. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe